Search research articles
Contact Us
Filters
Showing results (41-50 of 336) with videos related to
Page
of 34
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2007
Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy?
N Lynn Henry, Daniel F Hayes
Transactions of the American Clinical and Climatological Association
|
September 3, 2015
Personalized Medicine: Genomics Trials in Oncology
Daniel F Hayes, Anne F Schott
The Journal of Clinical Investigation
|
December 15, 2022
Expanding the reach of HER2-targeted therapies: transformation of an historical paradigm
Erin F Cobain, Daniel F Hayes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2022
Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Erin F Cobain, Daniel F Hayes
Cancer Investigation
|
February 9, 2008
The prognostic implications of circulating tumor cells in patients with breast cancer
Jeffrey B Smerage, Daniel F Hayes
Seminars in Oncology
|
June 14, 2002
c-erbB-2 in breast cancer: development of a clinically useful marker
Daniel F Hayes, Ann D Thor
Current Treatment Options in Oncology
|
May 2, 2015
Indications for prognostic gene expression profiling in early breast cancer
Erin F Cobain, Daniel F Hayes
The Oncologist
|
January 6, 2021
Completing the Translation
Robert T McCormack, Daniel F Hayes
Molecular Oncology
|
February 24, 2012
Cancer biomarkers
N Lynn Henry, Daniel F Hayes
Journal of the National Cancer Institute
|
September 2, 2011
Do all patients with breast cancer require systemic adjuvant therapy?
Jennifer J Griggs, Daniel F Hayes
Page
of 34
Search research articles
Search
Showing results (41-50 of 336) with videos related to
Sort By:
Page
of 34
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2007
Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy?
N Lynn Henry, Daniel F Hayes
Transactions of the American Clinical and Climatological Association
|
September 3, 2015
Personalized Medicine: Genomics Trials in Oncology
Daniel F Hayes, Anne F Schott
The Journal of Clinical Investigation
|
December 15, 2022
Expanding the reach of HER2-targeted therapies: transformation of an historical paradigm
Erin F Cobain, Daniel F Hayes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2022
Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Erin F Cobain, Daniel F Hayes
Cancer Investigation
|
February 9, 2008
The prognostic implications of circulating tumor cells in patients with breast cancer
Jeffrey B Smerage, Daniel F Hayes
Seminars in Oncology
|
June 14, 2002
c-erbB-2 in breast cancer: development of a clinically useful marker
Daniel F Hayes, Ann D Thor
Current Treatment Options in Oncology
|
May 2, 2015
Indications for prognostic gene expression profiling in early breast cancer
Erin F Cobain, Daniel F Hayes
The Oncologist
|
January 6, 2021
Completing the Translation
Robert T McCormack, Daniel F Hayes
Molecular Oncology
|
February 24, 2012
Cancer biomarkers
N Lynn Henry, Daniel F Hayes
Journal of the National Cancer Institute
|
September 2, 2011
Do all patients with breast cancer require systemic adjuvant therapy?
Jennifer J Griggs, Daniel F Hayes
Page
of 34